


In the claims

Please cancel claims 1-14, 16, 21, 23, 28, 30, 35, 37, 42, and 44-54 without prejudice.

Pursuant to 37 C.F.R. § 1.121(c)(1), please amend claims 15, 22, 29, 36, and 43 as set forth below. A marked-up version of the amended claims, showing the changes made, follows the Conclusion section of the instant Amendment and Response.

15. (amended) A polypharmacophore represented by formula (II):



(II)

wherein:


R<sub>1</sub> is selected from the group consisting of aryl, aralkyl, aralkenyl, -CO<sub>2</sub>H, amido, and ester;

R<sub>2</sub> is selected from the group consisting of aralkyl and aralkenyl; and

R<sub>3</sub> is selected from the group consisting of aryl, amine, and ether;

wherein one or none of R<sub>1</sub>, R<sub>2</sub>, or R<sub>3</sub> comprises a modifier unit selected from the group consisting of lipids, antibodies, lectins, sugars, steroids, hormones, proteins, biotin, folate, riboflavincarnitine, inositol, lipoic acid, niacin, pantothenic acid, thiamin, pyridoxal, ascorbic acid, heptens, epitopes, dsDNA fragments, and vitamins A, D, E, and K, whereby the polypharmacophore interacts with at least two biological targets.

22. (amended) A polypharmacophore represented by formula (IIA):



(IIA)

wherein:

*a3*  
*cancel*  
R<sub>1</sub> is selected from the group consisting of H, aryl, aralkyl, aralkenyl, CO<sub>2</sub>H, amido, and ester;


R<sub>2</sub> is selected from the group consisting of aralkyl and aralkenyl; and

R<sub>3</sub> is selected from the group consisting of aryl, amine, and ether;

one or none of R<sub>1</sub>, R<sub>2</sub>, or R<sub>3</sub> comprise a modifier unit; and D comprises an additional modifier unit, wherein the modifier units are selected from the group consisting of lipids, antibodies, lectins, sugars, steroids, hormones, proteins, biotin, folate, riboflavin, carnitine, inositol, lipoic acid, niacin, pantothenic acid, thiamin, pyridoxal, ascorbic acid, heptens, epitopes, dsDNA fragments, and vitamins A, D, E, and K; and

wherein a, b, and c are each independently greater than or equal to zero, whereby the polypharmacophore interacts with at least two biological targets.

29. (amended) A polypharmacophore represented by formula (III):




a4  
conced.

(III)

wherein at least two of A, B, or C comprise a pharmacophore; and wherein one or none of A, B, or C comprise a modifier unit, whereby the polypharmacophore interacts with at least two biological targets.

36. (amended) A polypharmacophore represented by formula (IIIA):



wherein at least two of A, B, or C comprise a pharmacophore; one or none of A, B, or C comprise a modifier unit; and D comprises an additional modifier unit, wherein a, b, and c are each independently greater than or equal to zero, whereby the polypharmacophore interacts with at least two biological targets.

43. (amended) A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 22, 29, or 36, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable diluent or carrier.